Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

---

Copy For Citation

Kilickap S., Sezer A., Gumus M., Bondarenko I., Ozguroglu M., Gogishvili M., ...More

JOURNAL OF THORACIC ONCOLOGY, vol.16, no.3, 2021 (SCI-Expanded)

• Publication Type: Article / Abstract
• Volume: 16 Issue: 3
• Publication Date: 2021
• Journal Name: JOURNAL OF THORACIC ONCOLOGY
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
• Hacettepe University Affiliated: Yes